Skip to content
Medical Health Aged Care

WA Labor releases plan to break barriers to ADHD diagnosis and treatment by GPs

Royal Australian College of GPs 2 mins read

Specialist GPs will be able to diagnose attention deficit hyperactivity disorder (ADHD) and initiate and manage its treatment with stimulant medication under proposed WA Labor reforms hailed as a breakthrough for patients by Australia’s peak body for general practice.

WA Labor worked closely with the Royal Australian College of GPs (RACGP) to develop the proposal and has committed to implementing it in consultation with specialist GPs if returned to government at the state election on 8 March.

If the proposed changes are implemented, patients will be able to receive a diagnosis and treatment from specialist GPs with a specific skills in ADHD and peer support from specialist paediatricians or psychiatrists. Currently, patients must receive a diagnosis from a psychiatrist or paediatrician.

RACGP WA Chair and Vice President Dr Ramya Raman said the proposal is a welcome step forward.

“This proposal is the culmination of extensive discussions and work by GPs and the WA Government, but more importantly, calls from our patients for support to access potentially lifechanging treatment,” she said.

“Patients need ongoing support for complex conditions like ADHD. If implemented well, this initiative will be a big step forward for Western Australians.

“ADHD is estimated to cost Australians $20 billion every year. That includes both direct health costs and more abstract factors like its impacts on productivity, but we can’t lose sight of the human side. It’s stressful to manage a complex condition and it is important for patients to have all the support around them.

“Patients deserve ongoing access to care through their specialist GP, who knows them and their history. This proposal can enable that for people living with ADHD.

Dr Raman reiterated calls for all political parties to back the RACGP’s plan for accessible and affordable GP care, which will benefit patients with complex conditions like ADHD.

Modelling commissioned by the College shows boosting Medicare rebates for consultations longer than 20 minutes by 40% will halve out-of-pocket-costs, saving patients $268 million annually and improving access to treatment for complex conditions.

“General practice must be well funded to be effective – for the upcoming federal election, we’re calling on all parties to commit to significant investment in Medicare, including boosting funding for long consults,” Dr Raman said.

“Patients living with ADHD, especially those who are considering an assessment, identified enormous hurdles in the previous Senate inquiry.

“Other governments and parties across our states and territories should be taking notes and talking to their GPs.”

With long wait lists and costs creating barriers to potentially lifechanging treatment for ADHD – and unneeded stress for patients – the RACGP has previously:

~ENDS


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

Contact: 03 8699 0992[email protected]

Follow us on Twitter: @RACGP and Facebook.

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.